Epygon Biomimetic Mitral Valve
Treatment of Mitral Regurgitation
Clinical EvaluationPromising results presented at TCT 2025
Key Facts
Indication
Treatment of Mitral Regurgitation
Phase
Clinical Evaluation
Status
Promising results presented at TCT 2025
Company
About Carvolix
Carvolix is a publicly traded French MedTech company founded by Truffle Capital with the ambition to become a global leader in treating structural heart disease and ischemic stroke. The company leverages a unique business builder model, integrating three synergistic entities (Caranx Medical, Artedrone, and its legacy business) to develop AI- and imaging-driven mini-robots and next-generation heart valves. With its first product, TAVIPILOT Soft, already FDA-cleared and in commercial use, and a robotic system in clinical trials, Carvolix is positioned to address massive treatment gaps in TAVI, mitral regurgitation, and mechanical thrombectomy.
View full company profileTherapeutic Areas
Other Treatment of Mitral Regurgitation Drugs
| Drug | Company | Phase |
|---|---|---|
| Robotically Delivered Mitral Valve | Carvolix | Research & Development |